Rezultati pretraživanja
  1. Study with et al quantified commercial tweeting (big pharma & biotech) at a major international conference (). We excluded these tweets to study content of scientific & clinical interest.

  2. SOLO-1 results support benefits maintenance olaparib in pts with BRCA mutation.

  3. 17. pro 2018.

    We will be sharing some of the top studies of 2018. Here's the first one: our Javelin Renal 101 infographic from .

  4. 31. ožu 2019.
    Odgovor korisniku/ci

    Thank you for stressing this!!!! Statement #2 cannot be undervalued! study by nicely showed LOH scores in BRCA2mut vary in different tumor type

  5. 27. ruj 2019.

    Secondary outcome results of RADICALS trial w med 5 yr F/U: similar PSA recurrence and need for salvage ADT to date, more tox adjuvant can’t wait for primary endpoint MFS

  6. Ready for the amazing Presidential Lung Session! FLAURA and CheckMate 227 the trials that will be present very soon!

  7. 16. sij 2019.

    Great talk on the management of immunotherapy toxicity management . Especially helpful for the more complex cases I am starting to see as inpatients.

  8. ready to start!On there is just a lot of traffic!Only y-day 1249 tweet with t official hashtag! in is growing fast improving medical cultural exchange & snap WW interactions.Coming soon published twitter analysis.Stay tuned

  9. 16. sij 2019.
  10. 11. velj 2019.

    niraparib in mCRPC data abstract out for ASCO 38% (5/13) ORR in BRCAm patients vs 44% (11/25) ORR at

  11. 16. pro 2018.

    Alpelisib and fulvestrant phase I published in JAMA Oncol! Great timing after presentation of early data from SOLAR-1 at . Great collaboration with Cornelia Quadt, Dejan Juric, , Jordi Rodon and others.

  12. Just out in the first data of effect on the ovarian reserve measured by levels of young -mutated patients: important data to improve the counseling of these women

  13. Congrats to et al. for publishing the trial (presented at ) in : important data on the role of plus (with or with ) in premenopausal patients

  14. is leading the GI Med Onc group and GI Cancer Research Program , Chair Survivorship Guideline panel, submitted a grant 🤞, poster , received the Rodger Winn award from the NCCN her my work with the organization. /39

    Prikaži ovu nit
  15. 18. pro 2018.
  16. 11. lip 2019.
    Odgovor korisnicima

    Later lines of therapy were not reported, but great question. Agree ORR is low (16% pembro vs 36% chemo). ORR in chemoIO ITT not reported at ASCO (just PDL1+), reported ORR of 35.6% for chemoIO at . Patient selection and biomarkers are critical

  17. 16. sij 2019.
  18. 17. pro 2018.

    This past weekend SQZ won best cell therapy poster at Congress. The winning poster described data demonstrating the benefits of the SQZ cell therapy approach over electroporation for modifying immune cells.

  19. 28. ruj 2019.

    Another excellent session from at this morning about current and future radionuclide therapy. Really engaged audience made for great discussion session. Ending my day at conference by mixing it up and seeing what we can learn from pancreatic cancer.

  20. Will wait to see comparison and more numbers pertaining to longer followup. Previously reported numbers regarding the combination of VEGF⛔️➕PDL1⛔️ & earlier phase study . Does appear to become an option besides TKIs.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.